Register for our free email digests:
Shionogi & Co. Ltd.
www.shionogi.co.jp
Latest From Shionogi & Co. Ltd.
Asahi Paying $1.3bn For One-Product Veloxis
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
New Tech Payment For Old Antibiotics: US Medicare Effort Brings Lots Of Interest
CMS streamlined process for enhanced payments is having an impact: seven antibiotic applications for New Technology Add-On Payment status in 2021—including one for a product that has been marketed for more than five years.
CNS 'Graveyard Of Drug Development' Needs Oncology-Like FDA Regulatory Approach
Lundbeck executive calls for adaptive trial designs, transdiagnostic approach, and more scientific discussions between sponsors and the US Food and Drug Administration.
Keeping Track Of User Fee Decisions And Filings: Adakveo, Brukinsa And Fetroja Mark Massive Week Of Novel Approvals
The latest news on US FDA user fee decisions and submissions to the agency.
Company Information
- Industry
- Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Cancer
- Gynecological, Urological
- Immune Disorders
- Infectious & Viral Diseases
- Metabolic Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
Asia
-
Pacific Rim
-
Japan
-
Japan
-
Pacific Rim
-
Asia
- Company Type
- Top Japanese Pharma
- Parent & Subsidiaries
- Shionogi & Co. Ltd.
- Senior Management
- Isao Teshirogi, PhD, Pres. & CEO
- Contact Info
-
Shionogi & Co. Ltd.
Phone: (81) 6 6202 2161
1-8, Doshomachi 3-chome
Chuo-ku
Osaka, 541 0045
Japan
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice